Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 105

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Recent Advances in Dyspnea

Mahler, Donald A., O'Donnell, Denis E.·2015·Chest
DOI 10.1378/chest.14-0800
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1378/chest.14-0800

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 78

  1. Kessler, 2011, Symptom variability in patients with severe COPD: a pan-European cross-sectional study, Eur Respir J, 37, 264, 10.1183/09031936.00051110 · DOI
  2. Hayen, 2013, Understanding dyspnea as a complex individual experience, Maturitas, 76, 45, 10.1016/j.maturitas.2013.06.005 · DOI
  3. Ward, 2010, Women's mid-life health experiences in urban UK: an international comparison, Climacteric, 13, 278, 10.3109/13697130903197479 · DOI
  4. Ingle, 2012, Body mass index is related to the perception of exertional breathlessness in patients presenting with dyspnoea of unknown origin, Int J Cardiol, 157, 300, 10.1016/j.ijcard.2012.03.113 · DOI
  5. Zutler, 2012, Relationship of obesity with respiratory symptoms and decreased functional capacity in adults without established COPD, Prim Care Respir J, 21, 194, 10.4104/pcrj.2012.00028 · DOI
  6. O'Donnell, 2014, When obesity and chronic obstructive pulmonary disease collide. Physiological and clinical consequences, Ann Am Thorac Soc, 11, 635, 10.1513/AnnalsATS.201312-438FR · DOI · Paper page
  7. Hanania, 2011, Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study investigators Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort, Am J Respir Crit Care Med, 183, 604, 10.1164/rccm.201003-0472OC · DOI
  8. Nguyen, 2013, Patients with COPD with higher levels of anxiety are more physically active, Chest, 144, 145, 10.1378/chest.12-1873 · DOI
  9. Yohannes, 2010, Depression and anxiety in chronic heart failure and chronic obstructive pulmonary disease: prevalence, relevance, clinical implications and management principles, Int J Geriatr Psychiatry, 25, 1209, 10.1002/gps.2463 · DOI
  10. von Leupoldt, 2011, The impact of anxiety on the neural processing of respiratory sensations, Neuroimage, 55, 247, 10.1016/j.neuroimage.2010.11.050 · DOI
  11. Nishimura, 2002, Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD, Chest, 121, 1434, 10.1378/chest.121.5.1434 · DOI
  12. Argulian, 2014, Meta-analysis of prognostic implications of dyspnea versus chest pain in patients referred for stress testing, Am J Cardiol, 113, 559, 10.1016/j.amjcard.2013.10.019 · DOI
  13. Berraho, 2013, Dyspnea: a strong independent factor for long-term mortality in the elderly, J Nutr Health Aging, 17, 908, 10.1007/s12603-013-0347-6 · DOI
  14. O'Donnell, 2009, Mechanisms of activity-related dyspnea in pulmonary diseases, Respir Physiol Neurobiol, 167, 116, 10.1016/j.resp.2009.01.010 · DOI · Paper page
  15. Gifford, 2011, Neuromodulatory effect of endogenous opioids on the intensity and unpleasantness of breathlessness during resistive load breathing in COPD, COPD, 8, 160, 10.3109/15412555.2011.560132 · DOI
  16. Mahler, 2009, Endogenous opioids modify dyspnoea during treadmill exercise in patients with COPD, Eur Respir J, 33, 771, 10.1183/09031936.00145208 · DOI
  17. Mahler, 2013, Effect of increased blood levels of β-endorphin on perception of breathlessness, Chest, 143, 1378, 10.1378/chest.12-1541 · DOI
  18. Mahler, 2014, Antagonism of substance P and perception of breathlessness in patients with chronic obstructive pulmonary disease, Respir Physiol Neurobiol, 196, 1, 10.1016/j.resp.2014.02.008 · DOI
  19. Herigstad, 2011, Dyspnoea and the brain, Respir Med, 105, 809, 10.1016/j.rmed.2010.12.022 · DOI
  20. Ciavaglia, 2014, Does exercise test modality influence dyspnoea perception in obese patients with COPD?, Eur Respir J, 43, 1621, 10.1183/09031936.00151513 · DOI · Paper page
  21. Holm, 2014, Effect of modality on cardiopulmonary exercise testing in male and female COPD patients, Respir Physiol Neurobiol, 192, 30, 10.1016/j.resp.2013.11.009 · DOI
  22. Guenette, 2012, Does dynamic hyperinflation contribute to dyspnoea during exercise in patients with COPD?, Eur Respir J, 40, 322, 10.1183/09031936.00157711 · DOI · Paper page
  23. O'Donnell, 2012, Decline of resting inspiratory capacity in COPD: the impact on breathing pattern, dyspnea, and ventilatory capacity during exercise, Chest, 141, 753, 10.1378/chest.11-0787 · DOI · Paper page
  24. Laveneziana, 2011, Evolution of dyspnea during exercise in chronic obstructive pulmonary disease: impact of critical volume constraints, Am J Respir Crit Care Med, 184, 1367, 10.1164/rccm.201106-1128OC · DOI
  25. Gagnon, 2012, Influences of spinal anesthesia on exercise tolerance in patients with chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 186, 606, 10.1164/rccm.201203-0404OC · DOI
  26. Vestbo, 2013, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary, Am J Respir Crit Care Med, 187, 347, 10.1164/rccm.201204-0596PP · DOI · Paper page
  27. Han, 2013, GOLD 2011 disease severity classification in COPDGene: a prospective cohort study, Lancet Respir Med, 1, 43, 10.1016/S2213-2600(12)70044-9 · DOI
  28. Agusti, 2013, ECLIPSE Investigators Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort, Eur Respir J, 42, 636, 10.1183/09031936.00195212 · DOI
  29. O'Donnell, 2007, Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease-2007 update, Can Respir J, 14, 5B
  30. Miravitlles, 2013, A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC), Prim Care Respir J, 22, 117, 10.4104/pcrj.2013.00016 · DOI
  31. Blackwell, 2014, Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report, Am J Respir Crit Care Med, 189, 214, 10.1164/rccm.201306-1141WS · DOI
  32. McLaughlin, 2009, J Am Coll Cardiol, 53, 1573, 10.1016/j.jacc.2009.01.004 · DOI
  33. Beeh, 2011, Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD, COPD, 8, 340, 10.3109/15412555.2011.594464 · DOI
  34. Beeh, 2012, Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial, Int J Chron Obstruct Pulmon Dis, 7, 503, 10.2147/COPD.S32451 · DOI
  35. Beeh, 2014, Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study, Respir Med, 108, 584, 10.1016/j.rmed.2014.01.006 · DOI · Paper page
  36. Maltais, 2011, Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD, Respir Med, 105, 580, 10.1016/j.rmed.2010.11.019 · DOI · Paper page
  37. Worth, 2010, Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD, Respir Med, 104, 1450, 10.1016/j.rmed.2010.07.006 · DOI
  38. O'Donnell, 2011, INABLE 1 study group Effect of indacaterol on exercise endurance and lung hyperinflation in COPD, Respir Med, 105, 1030, 10.1016/j.rmed.2011.03.014 · DOI · Paper page
  39. Cazzola, 2008, American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD Outcomes for COPD pharmacological trials: from lung function to biomarkers, Eur Respir J, 31, 416, 10.1183/09031936.00099306 · DOI
  40. Dahl, 2010, INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD, Thorax, 65, 473, 10.1136/thx.2009.125435 · DOI
  41. Kornmann, 2011, INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-μg Doses with COPD Patients) study investigators Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison, Eur Respir J, 37, 273, 10.1183/09031936.00045810 · DOI
  42. Gotfried, 2012, Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies, COPD, 9, 629, 10.3109/15412555.2012.729623 · DOI
  43. Kinoshita, 2012, Indacaterol Asian COPD Study Investigators Efficacy and safety of indacaterol 150 and 300 μg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study, Respirology, 17, 379, 10.1111/j.1440-1843.2011.02107.x · DOI
  44. Donohue, 2010, INHANCE Study Investigators Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium, Am J Respir Crit Care Med, 182, 155, 10.1164/rccm.200910-1500OC · DOI
  45. Kerwin, 2012, ACCORD I study investigators Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I), COPD, 9, 90, 10.3109/15412555.2012.661492 · DOI
  46. Jones, 2012, Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study, Eur Respir J, 40, 830, 10.1183/09031936.00225511 · DOI
  47. D'Urzo, 2011, Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial, Respir Res, 12, 156, 10.1186/1465-9921-12-156 · DOI
  48. Kerwin, 2012, Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study, Eur Respir J, 40, 1106, 10.1183/09031936.00040712 · DOI
  49. Donohue, 2013, Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD, Respir Med, 107, 1538, 10.1016/j.rmed.2013.06.001 · DOI
  50. Mahler, 2014, Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study, Eur Respir J, 43, 1599, 10.1183/09031936.00124013 · DOI
  51. Celli, 2014, Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study, Chest, 145, 981, 10.1378/chest.13-1579 · DOI
  52. Mahler, 2005, The MCID of the transition dyspnea index is a total score of one unit, COPD, 2, 99, 10.1081/COPD-200050666 · DOI
  53. Kerwin, 2013, A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD, Respir Med, 107, 560, 10.1016/j.rmed.2012.12.014 · DOI
  54. Martinez, 2013, Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial, Respir Med, 107, 550, 10.1016/j.rmed.2012.12.016 · DOI
  55. Swigris, 2012, Patient-reported outcomes in idiopathic pulmonary fibrosis research, Chest, 142, 291, 10.1378/chest.11-2602 · DOI
  56. Raghu, 2010, Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1), Eur Respir J, 35, 118, 10.1183/09031936.00188108 · DOI
  57. Wadell, 2013, Impact of pulmonary rehabilitation on the major dimensions of dyspnea in COPD, COPD, 10, 425, 10.3109/15412555.2012.758696 · DOI
  58. Mahler, 2013, Opioids for refractory dyspnea, Expert Rev Respir Med, 7, 123, 10.1586/ers.13.5 · DOI
  59. Mahler, 2010, American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease, Chest, 137, 674, 10.1378/chest.09-1543 · DOI
  60. Marciniuk, 2011, Canadian Thoracic Society COPD Committee Dyspnea Expert Working Group Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline, Can Respir J, 18, 69
  61. Banzett, 2011, Using laboratory models to test treatment: morphine reduces dyspnea and hypercapnic ventilatory response, Am J Respir Crit Care Med, 184, 920, 10.1164/rccm.201101-0005OC · DOI
  62. Oxberry, 2011, Short-term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial, Eur J Heart Fail, 13, 1006, 10.1093/eurjhf/hfr068 · DOI
  63. Oxberry, 2013, Repeat dose opioids may be effective for breathlessness in chronic heart failure if given for long enough, J Palliat Med, 16, 250, 10.1089/jpm.2012.0270 · DOI
  64. MA Pinna, E Bruera, MJ Moralo, MA Correas, RM Vargas, A randomized crossover clinical trial to evaluate the efficacy of oral transmucosal fentanyl citrate in the treatment of dyspnea on exertion in patients with advanced cancer [published online ahead of print November 20, 2013]. Am J Hosp Palliat Care, doi:10.1177/1049909113513063 · DOI
  65. Jensen, 2012, Inhaled fentanyl citrate improves exercise endurance during high-intensity constant work rate cycle exercise in chronic obstructive pulmonary disease, J Pain Symptom Manage, 43, 706, 10.1016/j.jpainsymman.2011.05.007 · DOI
  66. Ben-Aharon, 2012, Interventions for alleviating cancer-related dyspnea: a systematic review and meta-analysis, Acta Oncol, 51, 996, 10.3109/0284186X.2012.709638 · DOI
  67. Currow, 2011, Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study, J Pain Symptom Manage, 42, 388, 10.1016/j.jpainsymman.2010.11.021 · DOI
  68. Johnson, 2013, Opioids for chronic refractory breathlessness: patient predictors of beneficial response, Eur Respir J, 42, 758, 10.1183/09031936.00139812 · DOI
  69. Jones, 2011, Acute effects of Acu-TENS on FEV1 and blood β-endorphin level in chronic obstructive pulmonary disease, Altern Ther Health Med, 17, 8
  70. Suzuki, 2012, A randomized, placebo-controlled trial of acupuncture in patients with chronic obstructive pulmonary disease (COPD): the COPD-acupuncture trial (CAT), Arch Intern Med, 172, 878, 10.1001/archinternmed.2012.1233 · DOI
  71. Viswanathan, 2013, Cingulotomy for medically refractory cancer pain, Neurosurg Focus, 35, E1, 10.3171/2013.6.FOCUS13236 · DOI
  72. Pereira, 2014, Anterior cingulotomy improves malignant mesothelioma pain and dyspnea, Br J Neurosurg, 28, 471, 10.3109/02688697.2013.857006 · DOI
  73. Ninane, 2012, Multicentre European study for the treatment of advanced emphysema with bronchial valves, Eur Respir J, 39, 1319, 10.1183/09031936.00019711 · DOI
  74. Sciurba, 2010, VENT Study Research Group A randomized study of endobronchial valves for advanced emphysema, N Engl J Med, 363, 1233, 10.1056/NEJMoa0900928 · DOI
  75. Shah, 2014, Current status of bronchoscopic lung volume reduction with endobronchial valves, Thorax, 69, 280, 10.1136/thoraxjnl-2013-203743 · DOI
  76. Smith, 2014, Neuromodulation and palliative medicine, Am J Hosp Palliat Care, 31, 211, 10.1177/1049909113482745 · DOI
  77. Vieira, 2014, Neuromuscular electrical stimulation improves clinical and physiological function in COPD patients, Respir Med, 108, 609, 10.1016/j.rmed.2013.12.013 · DOI
  78. Porszasz, 2013, Physiologic effects of an ambulatory ventilation system in chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 188, 334, 10.1164/rccm.201210-1773OC · DOI

Cited by

Metadata

Authors
Mahler, D. A., & O'Donnell, D. E.
Venue
Chest
Publisher
Elsevier BV
Published
2015-01
Volume
147
Issue
1
Pages
232-241
ISSN
0012-3692
DOI
10.1378/chest.14-0800
Cited by
105
References
8
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.